Brean Murray began coverage on shares of Synta Pharmaceuticals Corp. (NASDAQ: SNTA) in a research note issued to investors on Thursday. The firm issued a buy rating and a $12.00 target price on the stock.
Several other analysts have also recently commented on the stock. Analysts at Jefferies Group raised their price target on shares of Synta Pharmaceuticals Corp. from $15.00 to $22.00 in a research note to investors on Monday, October 1st. They now have a buy rating on the stock.